<html><head></head><body><h1>Ryna-12 S</h1><p class="drug-subtitle"><b>Generic Name:</b> phenylephrine tannate and pyrilamine tannate<br/>
<b>Dosage Form:</b> tablet, oral suspension<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Side Effects</li>
<li>Dosage</li>
<li><b class="nav-item here">Professional</b></li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.</p><ul>
<li>Description</li>
<li>Clinical Pharmacology</li>
<li>Indications and Usage</li>
<li>Contraindications</li>
<li>Warnings</li>
<li>Precautions</li>
<li>Patient Counseling Information</li>
<li class="ddc-toggle-hidden">Drug Interactions</li>
<li class="ddc-toggle-hidden">Adverse Reactions/Side Effects</li>
<li class="ddc-toggle-hidden">Overdosage</li>
<li class="ddc-toggle-hidden">Dosage and Administration</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
</ul><h2>Description</h2><p class="First">RYNA®-12 is an antihistamine/nasal decongestant combination available for oral administration as <span class="Italics">Tablets</span> and as <span class="Italics">Suspension</span>. Each tablet contains:</p><p>Phenylephrine Tannate 25 mg<br/>
Pyrilamine Tannate        60 mg<br/>
Other ingredients: corn starch, dibasic calcium phosphate, magnesium stearate, methylcellulose, polygalacturonic acid, talc.</p><p>Each 5 mL (one teaspoonful) of the pink-colored, natural strawberry-artificial currant flavored Suspension contains:<br/>
Phenylephrine Tannate 5 mg<br/>
Pyrilamine Tannate        30 mg</p><p>Other ingredients: benzoic acid, FD&amp;C Red No. 3, flavors (natural and artificial), glycerin, kaolin, magnesium aluminum silicate, methylparaben, pectin, purified water, saccharin sodium, sucrose.</p><h2>Clinical Pharmacology</h2><p class="First">RYNA®-12 combines the sympathomimetic decongestant effect of phenylephrine with the antihistaminic action of pyrilamine.</p><h2>Indications and Usage</h2><p class="First">RYNA®-12 is indicated for symptomatic relief of the coryza and nasal congestion associated with the common cold, sinusitis, allergic rhinitis and other upper respiratory tract conditions. Appropriate therapy should be provided for the primary disease.</p><h2>Contraindications</h2><p class="First">RYNA®-12 is contraindicated for newborns, nursing mothers and patients sensitive to any of the ingredients or related compounds.</p><h2>Warnings</h2><p class="First">Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma or prostatic hypertrophy. Use with caution or avoid use in patients taking monoamine oxidase (MAO) inhibitors, or within 14 days of stopping such treatment. These products contain an antihistamine which may cause drowsiness and may have additive central nervous system (CNS) effects with alcohol or other CNS depressants (e.g., hypnotics, sedatives, tranquilizers).</p><h2>Precautions</h2><p class="First"><span class="Italics">General:</span> Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients. Antihistamines may cause excitation, particularly in children, but their combination with sympathomimetics may cause either mild stimulation or mild sedation.</p><p class="First"><span class="Italics">Information for patients:</span> Caution patients against drinking alcoholic beverages or engaging in potentially hazardous activities requiring alertness, such as driving a car or operating machinery while using these products. Patients should be warned not to use these products if they are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If patients are uncertain whether a prescription drug contains an MAOI, they should be instructed to consult a health professional before taking such a product.</p><p class="First"><span class="Italics">Drug interactions:</span> MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines and the overall effects of sympathomimetic agents.</p><p class="First"><span class="Italics">Carcinogenesis, mutagenesis, impairment of fertility:</span> No long-term animal studies have been performed with RYNA®-12.</p><p class="First"><span class="Italics">Pregnancy:</span> Teratogenic effects: Pregnancy Category C. Animal reproduction studies have not been conducted with RYNA®-12. It is also not known whether RYNA®-12 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RYNA®-12 should be given to a pregnant woman only if clearly needed.</p><p class="First"><span class="Italics">Nursing mothers:</span> RYNA®-12 should not be administered to a nursing woman.</p><h2>Adverse Reactions</h2><p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or</span> <span class="Bold Italics Underline">www.fda.gov/medwatch</span>.</p><p>Adverse effects associated with RYNA®-12 at recommended doses have been minimal. The most common have been drowsiness, sedation, dryness of mucous membranes, and gastrointestinal effects. Serious side effects with oral antihistamines or sympathomimetics have been rare.</p><h2>Overdosage</h2><p class="First"><span class="Italics">Signs &amp; symptoms:</span> May vary from CNS depression to stimulation (restlessness to convulsions). Antihistamine overdosage in young children may lead to convulsions and death. Atropine-like signs and symptoms may be prominent.</p><p><span class="Italics">Treatment:</span> Induce vomiting if it has not occurred spontaneously. Precautions must be taken against aspiration especially in infants, children and comatose patients. If gastric lavage is indicated, isotonic or half-isotonic saline solution is preferred. Stimulants should not be used. If hypotension is a problem, vasopressor agents may be considered.</p><h2>Dosage and Administration</h2><p class="First">Administer the recommended dose every 12 hours.</p><p><span class="Italics">RYNA®-12</span> Tablets: Adults — 1 or 2 tablets.</p><p><span class="Italics">Children 6 to 11 years</span> — 1/2 or 1 tablet. <span class="Italics">Ryna-12 S</span> ® Suspension: <span class="Italics">Children over six years of age</span> — 5 to 10 mL (1 to 2 teaspoonfuls); <span class="Italics">Children two to six years of age</span> — 2.5 to 5 mL (1/2 to 1 teaspoonful); <span class="Italics">Children under two years of age</span> — Titrate dose individually.</p><h2>How Supplied</h2><p class="First">RYNA®-12 Tablets (phenylephrine tannate 25 mg, and pyrilamine tannate 60 mg): buff-colored, capsule-shaped, scored on one side and imprinted WALLACE 673 on the other side. The tablets are available in bottles of 100 (NDC 0037-0673-10).</p><p>Ryna-12 S® Suspension (phenylephrine tannate 5 mg, and pyrilamine tannate 30 mg per 5 mL) in 4 fl oz <span class="Bold">unit of use</span> container with a 10 mL graduated oral syringe and fitment (NDC 0037-0655-04, labeled Ryna-12 S®).</p><p class="First"><span class="Italics">Storage:</span> RYNA®-12 Tablets — Store at controlled room temperature 20°-25°C (68°-77°F).</p><p>Ryna-12 S® Suspension — Store at controlled room temperature 20°-25°C (68°-77°F).</p><p>U.S. Patent 6,287,597<br/>
Produced under license from<br/>
JFC Technologies<br/>
Bound Brook, NJ, U.S.A.<br/>
U.S. Patents 5,599,846; 5,663,415</p><p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or</span> <span class="Bold Italics Underline">www.fda.gov/medwatch</span>.</p><p><span class="Bold">MEDA<br/>
PHARMACEUTICALS<span class="Sup">®</span><br/>
Meda Pharmaceuticals Inc.</span><br/>
Somerset, New Jersey 08873-4120</p><p>Printed in U.S.A.        Rev. 3/09</p><h2>Package Label - Principal Display Panel – 4 fl. oz. Bottle, Ryna-12 S Suspension</h2><p class="First">NDC 0037-0655-04<br/>
<span class="Bold">4 fl oz (118 mL)<br/>
Ryna-12 S<span class="Sup">®</span><br/>
SUSPENSION</span><br/>
Each 5 mL (teaspoonful)<br/>
contains:<br/>
Phenylephrine Tannate    5 mg<br/>
Pyrilamine Tannate           30 mg<br/>
U.S. Patent 6,287,597<br/>
<span class="Bold">R<span class="Sub">x</span> Only<br/>
SHAKE WELL</span><br/>
LB-065504-04           Rev. 10/03<br/>
<span class="Bold">Usual Dosage:</span><br/>
See full prescribing information on bottom of tray.<br/>
See enclosed patient instructions for use of fitment and syringe.<br/>
Store at controlled room temperature 20°-25°C (68°-77°F).<br/>
Produced under license from<br/>
JFC Technologies<br/>
Bound Brook, NJ, U.S.A.<br/>
U.S. Patents 5,599,846; 5,663,415<br/>
<span class="Bold">MedPointe Pharmaceuticals<br/>
MedPointe Healthcare Inc.</span><br/>
Somerset, New Jersey 08873</p><p></p><h2>Package Label - Principal Display Panel – 100-ct Bottle, Ryna-12 Tablets</h2><p class="First">NDC 0037-0673-10<br/>
<span class="Bold">100 Tablets<br/>
RYNA<span class="Sup">®</span>-12</span><br/>
Each tablet contains:<br/>
Phenylephrine Tannate    25 mg<br/>
Pyrilamine Tannate           60 mg<br/>
U.S. Patent 6,287,597<br/>
<span class="Bold">R<span class="Sub">x</span> Only</span><br/>
LB-067310-02           Rev. 10/03<br/>
<span class="Bold">USUAL DOSE:</span> See package insert.<br/>
Store at controlled room tempera-<br/>
ture 20°-25°C (68°-77°F).<br/>
Protect from moisture.<br/>
Dispense in a tight container.<br/>
Produced under license from<br/>
JFC Technologies<br/>
Bound Brook, NJ, U.S.A.<br/>
U.S. Patents 5,599,846; 5,663,415<br/>
<span class="Bold">MedPointe Pharmaceuticals<br/>
MedPointe Healthcare Inc.</span><br/>
Somerset, New Jersey 08873</p><p></p><h2>More about Ryna-12S (phenylephrine / pyrilamine)</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: upper respiratory combinations</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Allergic Rhinitis</li>
<li>Allergies</li>
<li>Cold Symptoms</li>
<li>Nasal Congestion</li>
<li>Sinusitis</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>